Attached files

                                   EXHIBIT 99





CEL-SCI CORPORATION
8229 Boone Boulevard, Suite 802                          COMPANY CONTACT:
Vienna, VA  22182.  USA                                  Gavin de Windt
Telephone (703) 506-9460                                 CEL-SCI Corporation
www.cel-sci.com                                          (703) 506-9460

                  CEL-SCI ANNOUNCES THAT NYSE MKT APPROVES PLAN

Vienna,  VA, September 3, 2013 - CEL-SCI  Corporation  (NYSE MKT: CVM) announces
that the NYSE MKT (the  "Exchange")  has  accepted the  Company's  plan to bring
itself into compliance with the Exchange's continued listing standards.

The  Company  previously  received  notice from the  Exchange on July 18,  2013,
indicating that the Company is not in compliance with Section 1003(a)(iv) of the
Exchange's  continued  listing  standards in the Company Guide.  The Company was
afforded the  opportunity to submit a plan to regain  compliance,  and on August
19, 2013 the Company submitted its plan to the Exchange.

On August 30,  2013,  the  Exchange  notified  the Company  that it accepted the
Company's  plan of  compliance  and  granted  the  Company  an  extension  until
September 30, 2013 to regain  compliance with the continued  listing  standards.
The Company  will be subject to periodic  review  during the  extension  period.
Failure to make progress  consistent with the plan or to regain  compliance with
the continued  listing standards by the end of the extension period could result
in the Company being delisted from the NYSE MKT.

About CEL-SCI Corporation

CEL-SCI is  dedicated  to research and  development  directed at  improving  the
treatment  of cancer and other  diseases by  utilizing  the immune  system,  the
body's natural defense  system.  Its lead  investigational  therapy is Multikine
(Leukocyte Interleukin,  Injection), currently being studied in a pivotal global
Phase  III  clinical  trial.  CEL-SCI  is also  investigating  an  immunotherapy
(LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized  patients and as a
vaccine (CEL-2000) for Rheumatoid  Arthritis  (currently in preclinical testing)
using  its  LEAPS  technology   platform.   The  investigational   immunotherapy
LEAPS-H1N1-DC  treatment  involves  non-changing  regions of H1N1  Pandemic Flu,
Avian Flu (H5N1),  and the Spanish Flu, as CEL-SCI scientists are very concerned
about the possible  emergence of a new more  virulent  hybrid virus  through the
combination  of H1N1 and Avian  Flu,  or maybe  Spanish  Flu.  The  Company  has
operations in Vienna,  Virginia, and in/near Baltimore,  Maryland.


When used in this report,  the words "intends,"  "believes,"  "anticipated"  and
"expects"  and similar  expressions  are  intended  to identify  forward-looking
statements.  Such statements are subject to risks and uncertainties  which could
cause actual results to differ  materially  from those  projected.  Factors that
could cause or contribute to such differences include, an inability to duplicate
the clinical results demonstrated in clinical studies, timely development of any
potential  products  that  can be  shown  to be safe  and  effective,  receiving
necessary  regulatory  approvals,  difficulties  in  manufacturing  any  of  the
Company's potential  products,  inability to raise the necessary capital and the
risk factors set forth from time to time in CEL-SCI  Corporation's  SEC filings,
including  but not  limited  to its  report  on Form  10-K  for the  year  ended
September 30, 2012. The Company undertakes no obligation to publicly release the
result of any revision to these forward-looking  statements which may be made to
reflect  the events or  circumstances  after the date  hereof or to reflect  the
occurrence of unanticipated events.